1-15 of 15
Zongru Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Zongru Li, Lu Yu, Li-Juan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6121.
https://doi.org/10.1182/blood-2024-211874
Published: 2024
Journal Articles

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Lu Yu, Lijuan Hu, Zongru Li, Ting Zhao, Wenbing Duan, Jing Wang, JinSong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, LanPing Xu, Yu Wang, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 1537.
https://doi.org/10.1182/blood-2024-207269
Published: 2024
Journal Articles

Blinatumomab Combined with Venetoclax Increasing the Abundance of CD8 T Cell and NK Cell and Improve the Outcome in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Lijuan Hu, Ya-Zhe Wang, Xiang Wang, Zongru Li, Ting Zhao, Wenbing Duan, Lu Yu, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 2815.
https://doi.org/10.1182/blood-2024-211905
Published: 2024
Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4235.
https://doi.org/10.1182/blood-2024-209768
Published: 2024
Journal Articles

Immune-Related Signatures Predict Prognosis in Chronic Myeloid Leukemia (CML) Patients Receiving the 3 rd -Generation Tyrosine-Kinase Inhibitors (3G-TKIs)

Xiaoshuai Zhang, Zongru Li, Lu Yu, Mei Bao, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 3141.
https://doi.org/10.1182/blood-2024-203760
Published: 2024
Journal Articles

Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor- (TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy

Lu Yu, Lichuang Men, Zongru Li, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6358.
https://doi.org/10.1182/blood-2023-188406
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens

Zongru Li, Zhao Ting, Lijuan Hu, Wenbing Duan, Qian Jiang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5895.
https://doi.org/10.1182/blood-2023-185471
Published: 2023
Journal Articles

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

Xiaoshuai Zhang, Zongru Li, Ya-Zhen Qin, Robert Peter Gale, Yueyun Lai, Hongxia Shi, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9611–9613.
https://doi.org/10.1182/blood-2022-169397
Published: 2022
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Qian Jiang, Zongru Li, Ya-Zhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 198–199.
https://doi.org/10.1182/blood-2022-170868
Published: 2022
Journal Articles

Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy

Xiaoshuai Zhang, Zongru Li, Yazhen Qin, Robert Peter Gale, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2021) 138 (Supplement 1): 308.
https://doi.org/10.1182/blood-2021-150020
Published: 2021
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Jiang Qian, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yongping Song, Gongli Zhang, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yujun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3598.
https://doi.org/10.1182/blood-2021-153937
Published: 2021
Journal Articles

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

Jiang Qian, Dayu Shi, Zongru Li, Yazhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 311.
https://doi.org/10.1182/blood-2021-153065
Published: 2021
Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, MD, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, MD, Weiming Li, PhD, Xiaoli Liu, Na Xu, Yongping Song, MD, Yanli Zhang, Li Meng, MDPhD, Zhenya Hong, MDPhD, Bingcheng Liu, Shan Zeng, Lichuang Men, Yan Li, MD, Suning Chen, Mengxing Xue, PhD, Huanling Zhu, MD, He Li, Xin Du, Jin Lou, MD, Xiaohan Zhang, Yang Liang, MD, Yujun Dai, MD PhD, Ming Lu, PhD, Hengbang Wang, Jiao JI, PhD MD, Changai Yue, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142142
Published: 2020